Rsv Infection

Nirsevimab and the maternal vaccine for respiratory syncytial virus can reduce health care costs and productivity losses associated with RSV but lead to higher overall spending, according to analyses published in Pediatrics.

BOSTON — Infants who took nirsevimab had a reduced risk for respiratory syncytial virus lower respiratory tract disease, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

NEW YORK — In this video from the Infectious Diseases in Children Symposium, David W. Kimberlin, MD, provides an overview of the topics that were added to the 2024-2027 Red Book published earlier this year.

This is the second respiratory disease season with two new powerful tools to protect infants from severe respiratory syncytial virus disease, and experts are optimistic that uptake will improve from last season.

Older adults’ risk for death when hospitalized with respiratory syncytial virus is higher than it is for influenza B but similar to influenza A, according to a study.

The investigational antiviral ziresovir showed promise for the treatment of respiratory syncytial virus infection in infants during a phase 3 trial in China, researchers reported in The New England Journal of Medicine.